4 news items
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP
3 Jun 24
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
ABEO
ADAP
INBS
31 May 24
.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
- Prev
- 1
- Next